natgillin/translations-raw huggingface dataset:
Haemagglutination-inhibiting antibodies have been detected in 15100% of the immunised pigs on day 7 after primary immunisation which disappeared in the majority of animals within 1 to 4 weeks thereafter.
Pri 15-100 % imuniziranih prašičev so 7. dan po osnovni imunizaciji opazili hemaglutinacijo zavirajoča protitelesa, ki so nato pri večini živali izginila v 1 do 4 tednih.
4.2 Indication for use, specifying the target species
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah
PACKAGE LEAFLET FOR: RESPIPORC FLUpan H1N1 suspension for injection for pigs
NAVODILO ZA UPORABO RESPIPORC FLUpan H1N1 suspenzija za injiciranje za prašiče
FLUAV/Hamburg/NY1580/2009(H1N1)pdm09 (human origin), FLUAV/swine/Schallern/IDT19989/2014 (H1N1)pdm09 (swine origin) and FLUAV/sw/Teo(Spain)/AR641/2016 (H1N1)pdm09 (swine origin).
FLUAV/swine/Schallern/IDT19989/2014 (H1N1)pdm09 (prašičjega izvora) in FLUAV/sw/Teo(Spain)/AR641/2016 (H1N1)pdm09 (prašičjega izvora).
Neutralising antibodies in serum have been detected in more than 75% of the immunised pigs on day 7 after primary immunisation lasting in more than 75% of the pigs for over 3 months.
Pri več kot 75 % imuniziranih prašičev so 7. dan po osnovni imunizaciji opazili nevtralizirajoča protitelesa v serumu, ki so bila pri več kot 75 % prašičev prisotna več kot 3 mesece.
25 ml polyethylene terephthalate (PET) vials 50 ml PET vials
25-mililitrske viale iz polietilentereftalata (PET) 50-mililitrske viala iz PET
Duration of immunity: 3 months after primary vaccination.
3 mesece po osnovnem cepljenju.
Cardboard box with 1 vial of 25 doses (25 ml) or 50 doses (50 ml) with a rubber stopper and flanged cap.
Kartonasta škatla z 1 vialo s 25 odmerki (25 ml) ali 50 odmerki (50 ml) z gumijastim zamaškom ter prirobljeno zaporko.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA ODGOVOREN ZA SPROŠČANJE SERIJ
DATE OF FIRST AUTHORISATION
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO
Cardboard box with 1 polyethylene terephthalate (PET) vial of 25 doses (25 ml) or 50 doses (50 ml) with a rubber stopper and flanged cap.
Kartonasta škatla z 1 vialo iz polietilentereftalata (PET) s 25 odmerki (25 ml) ali 50 odmerki (50 ml) z gumijastim zamaškom ter prirobljeno zaporko.
Name and address of the manufacturer responsible for batch release
NEMČIJA Ime in naslov proizvajalca zdravila, odgovornega za sproščanje serij
Generally, maternally-derived antibodies induced by vaccination last for approximately 5-8 weeks after birth.
5-8 tednov po rojstvu.
Inactivated influenza A virus/human, strain A/Jena/VI5258/2009(H1N1)pdm09: ≥ 16 HU
Inaktivirani virus influence A (humani), sev A/Jena/VI5258/2009(H1N1)pdm09: ≥ 16 HU
Inactivated Influenza A virus/human Strain: A/Jena/VI5258/2009(H1N1)pdm09
Inaktivirani virus influence A (humani) Sev: A/Jena/VI5258/2009(H1N1)pdm09
Caps:
Zamaški:
Maternally-derived antibodies in piglets interfere with the RESPIPORC FLUpan H1N1 mediated immunity.
Maternalna protitelesa pri pujskih negativno vplivajo na imunost, izzvano s cepivom RESPIPORC
The antibody responses mentioned in the following have been documented in pigs without maternally-derived immunity.
Pri prašičih brez maternalne imunosti so zabeležili naslednje odzive protiteles.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
Stoppers:
Zaporke:
MARKETING AUTHORISATION HOLDER
IMETNIK(I) DOVOLJENJA ZA PROMET
A transient swelling up to 2 cm3 may occur at the site of injection, these reactions are common but resolve within 5 days.
Prehodna oteklina velikosti največ 2 cm3 se lahko pojavi na mestu injiciranja.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA
Efficacy of the vaccine was examined in laboratory challenge studies in pigs without maternallyderived antibodies and was demonstrated against the following strains;
Učinkovitost cepiva je bila raziskana v laboratorijskih provokacijskih študijah pri prašičih brez maternalnih protiteles in je bila dokazana proti naslednjim sevom: FLUAV/Hamburg/NY1580/2009(H1N1)pdm09 (humanega izvora),
The European Commission granted a marketing authorisation valid throughout the European Union for Lantus on 9 June 2000.
Evropska komisija je dovoljenje za promet z zdravilom Lantus, veljavno po vsej Evropski uniji, odobrila dne 9. junija 2000.
Other information about Lantus:
Druge informacije o zdravilu Lantus:
The full EPAR for Lantus can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lantus je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Lantus is given once a day.
Zdravilo Lantus se daje enkrat na dan.
Patients can inject themselves with Lantus if they have been trained appropriately.
Bolniki si lahko zdravilo Lantus vbrizgajo sami, če so bili za to ustrezno usposobljeni.
EPAR summary for the public insulin glargine
Povzetek EPAR za javnost insulin glargin
Reactions at the site of the injection (redness, pain, itching and swelling) and skin reactions (rash) have been seen more often in children than in adults.
Reakcije na mestu injiciranja (rdečina, bolečine, srbečica in otekanje) in kožne reakcije (izpuščaji) so bile pogosteje opažene pri otrocih kot pri odraslih.
In adults (aged 18 years or over), it can be given at any time, provided that it is at the same time each day.
Odrasli bolniki (stari 18 let ali več) lahko injekcijo prejmejo kadar koli čez dan, vendar vsak dan ob isti uri.
This document is a summary of the European Public Assessment Report (EPAR) for Lantus.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lantus.
The change means that it is absorbed more slowly and regularly by the body after an injection, and that it has a long duration of action.
Razlika se odraža v počasnejši in postopnejši absorpciji v telo po injiciranju ter v daljšem trajanju delovanja.
The effectiveness of Lantus was seen regardless of the time of the injection.
Opazili so, da je zdravilo Lantus učinkovito ne glede na čas injiciranja.
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.
Mesto injiciranja je treba pri vsakem naslednjem injiciranju menjati, da se preprečijo spremembe na koži (kot je odebelitev), zaradi česar lahko insulin deluje slabše od pričakovanega.
Insulin glargine is very slightly different from human insulin.
Insulin glargin se le malo razlikuje od človeškega insulina.
A total of 2,106 patients received Lantus in all trials combined.
Zdravilo Lantus je v vseh preskušanjih prejemalo skupno 2 106 bolnikov.
The patient's blood glucose (sugar) should be regularly tested to find the lowest effective dose.
Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da se določi najmanjši učinkoviti odmerek.
What benefit has Lantus shown during the studies?
Kakšne koristi je zdravilo Lantus izkazalo med študijami?
It should be given in the evening in patients aged less than 18 years.
Bolniki, mlajših od 18 let, morajo zdravilo prejeti zvečer.
Further studies have also been carried out to compare Lantus and human insulin NPH in patients with type 1 diabetes aged between five and 18 years, 200 of whom received Lantus, and in children aged two to six years, 61 of whom received Lantus.
Izvedene so bile tudi nadaljnje študije za primerjavo zdravila Lantus in človeškega insulina NPH pri bolnikih s sladkorno boleznijo tipa 1, starih od 5 do 18 let, med katerimi jih je 200 prejemalo zdravilo Lantus, in pri otrocih, starih od 2 do 6 let, med katerimi jih je 61 prejemalo zdravilo Lantus.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lantus.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Lantus, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The most common side effect with Lantus (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Najpogostejši neželeni učinek zdravila Lantus (opažen pri več kot 1 bolniku od 10) je hipoglikemija (nizka raven glukoze v krvi).
Studies have also been carried out in nearly 1,400 adults with type 1 or type 2 diabetes to measure the effectiveness of Lantus injected at any time during the day, compared with an injection given in the evening.
Študije so bile izvedene tudi pri skoraj 1 400 odraslih bolnikih s sladkorno boleznijo tipa 1 ali 2, da bi izmerili učinkovitost zdravila Lantus, injiciranega ob katerem koli času dneva, v primerjavi z injiciranjem pred spanjem.
The active substance in Lantus, insulin glargine, is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin glargine.
Zdravilno učinkovino v zdravilu Lantus, insulin glargin, proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori insulin glargin.
Lantus must not be used in people who are hypersensitive (allergic) to insulin glargine or to any of the other ingredients.
Zdravila Lantus ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) insulin glargin ali katero koli drugo sestavino zdravila.
All of the studies measured the level of ‘fasting' blood glucose (measured when the patients had not eaten for at least eight hours) or a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
V vseh študijah so merili raven glukoze v krvi na tešče (izmerjene vsaj osem ur po zadnjem obroku) ali snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako učinkovito je raven glukoze v krvi nadzorovana.
The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Nadomestni insulin deluje enako kot naravno proizvedeni insulin in omogoča, da lahko glukoza iz krvi preide v celice.
Injections of fast-acting insulin were also used at mealtimes.
V času obrokov so uporabili tudi injekcije hitro delujočega insulina.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose.
Sladkorna bolezen je bolezen, pri kateri telo ne tvori dovolj insulina za uravnavanje ravni glukoze v krvi.
Lantus was effective in managing diabetes in adults and children aged two years and above.
Zdravilo Lantus je bilo učinkovito pri uravnavanju sladkorne bolezni pri odraslih in otrocih, starih dve leti in več.
It is available as vials, cartridges and prefilled disposable pens (OptiSet and SoloStar).
Na voljo je v vialah, injekcijskih vložkih in napolnjenih injekcijskih peresnikih za enkratno uporabo (OptiSet in SoloStar).
Lantus was originally studied in 10 studies, in both type 1 diabetes (when the pancreas cannot produce insulin) and type 2 diabetes (when the body is unable to use insulin effectively).
Zdravilo Lantus so najprej proučili v 10 študijah, v katere so bili vključeni bolniki s sladkorno boleznijo tipa 1 (pri kateri trebušna slinavka ne more tvoriti insulina) in bolniki s sladkorno boleznijo tipa 2 (pri kateri telo ne more učinkovito izrabiti insulina).
Lantus is used to treat diabetes in patients aged two years or older.
Zdravilo Lantus se uporablja za zdravljenje sladkorne bolezni pri bolnikih, starih dve leti ali več.
Lantus doses might also need to be adjusted when given with some other medicines that may have an effect on blood glucose levels.
Odmerke zdravila Lantus bo morda treba prilagoditi, če se jemlje sočasno s katerim od drugih zdravil, ki vplivajo na raven sladkorja v krvi.
The CHMP decided that Lantus's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Lantus večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What is the risk associated with Lantus?
Kakšna tveganja so povezana z zdravilom Lantus?
The main studies compared Lantus given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
V glavnih študijah so primerjali prejemanje zdravila Lantus enkrat dnevno pred spanjem in prejemanje človeškega insulina NPH (srednjedolgo delujočega insulina) enkrat ali dvakrat dnevno.
Lantus led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with human insulin.
Zdravilo Lantus je znižalo ravni HbA1c, kar kaže, da so bile ravni glukoze v krvi uravnane na podobno raven kot pri človeškem insulinu.
Lantus is a replacement insulin that is very similar to the insulin made by the body.
Zdravilo Lantus je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja telo.
For the full list of all side effects reported with Lantus, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Lantus, glejte navodilo za uporabo.
In one study, patients with type 2 diabetes also received antidiabetes medicines by mouth.
V eni študiji so bolniki s sladkorno boleznijo tipa 2 prejeli tudi peroralna zdravila za sladkorno bolezen.
Lantus is given by injection under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (shoulder).
Zdravilo Lantus se injicira v podkožje trebušne stene (trebuha), stegna ali deltoidne mišice (ramena).
For more information about treatment with Lantus, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Lantus preberite navodilo za uporabo (ki je prav tako del EPAR).
Why has Lantus been approved?
Zakaj je bilo zdravilo Lantus odobreno?
Lantus is a solution for injection that contains the active substance insulin glargine.
Zdravilo Lantus je raztopina za injiciranje, ki vsebuje zdravilno učinkovino insulin glargin.
What is Lantus used for?
Za kaj se zdravilo Lantus uporablja?
How does Lantus work?
Kako zdravilo Lantus deluje?
How has Lantus been studied?
Kako je bilo zdravilo Lantus raziskano?
The full list is available in the package leaflet.
Za celoten seznam omejitev glejte navodilo za uporabo.
What is Lantus?
Kaj je zdravilo Lantus?
How is Lantus used?
Kako se zdravilo Lantus uporablja?
Lantus can also be given together with antidiabetes medicines taken by mouth in patients who have type 2 diabetes.
Pri bolnikih, ki imajo sladkorno bolezen tipa 2, lahko zdravilo Lantus dajemo sočasno s peroralnimi zdravili proti sladkorni bolezni.
Wear personal protective equipment.
Nosite osebno zaščitno opremo.
Remove contaminated clothing immediately.
Kontaminirana oblačila takoj odstranite.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu.
Store away from food.
Shranjujte ločeno od hrane.
ATCvet code: QP53AG03
Oznaka ATC vet: QP53AG03
The total amount of product administered to a colony should not exceed 54 ml.
Skupna količina zdravila, danega eni koloniji, ne sme presegati 54 ml.
Studies on the mode of action of oxalic acid are not available.
Študije o načinu delovanja oksalne kisline niso na voljo.
The outside temperature during treatment with Oxybee should be at least 3 °C.
Zunanja temperatura med zdravljenjem z zdravilom Oxybee mora biti vsaj 3 °C.
Used measuring devices and empty containers should be disposed of immediately in a proper way.
Uporabljene merilne pripomočke in prazne vsebnike je treba takoj in pravilno odstraniti.
Honey: Zero days.
Med: nič dni.
Shelf life after mixing according to directions: 1 year.
Rok uporabnosti po mešanju v skladu z navodili: 1 leto.
The concomitant use of other acaricidal products should be avoided because increased toxicity to bees might occur.
Treba se je izogibati sočasni uporabi drugih akaricidov, ker lahko pride do povečane toksičnosti za čebele.
An overdose of 53% of the dispersion per treatment resulted in a temporary, short-term increase in bee mortality.
53-odstotno preveliko odmerjanje disperzije na posamezno zdravljenje je privedlo do začasnega, kratkotrajnega povečanja umrljivosti čebel.
In case of accidental ingestion, clean the mouth with water and drink water or milk, but do not induce vomiting.
V primeru nenamernega zaužitja umijte usta z vodo in pijte vodo ali mleko, a ne sprožite bruhanja.
Preparation of the final dispersion:
Priprava končne disperzije:
The overdose did not significantly affect the development of the colonies in the long term, as shown by the development of the colonies in spring.
Preveliko odmerjanje ni pomembno vplivalo na dolgoročni razvoj kolonij, kot so dokazali z razvojem kolonij spomladi.
Wash hands and exposed skin with soap and plenty of water immediately.
Roke in izpostavljene dele kože si takoj umijte z milom in obilo vode.
It acts as contact poison against Varroa destructor.
Deluje kot kontaktni strup proti pršici Varroa destructor.
Avoid disturbing the hives in the days following treatment.
Družin v dneh po zdravljenju ne motite.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <Date of first authorisation:> 01/02/2018
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET <Datum pridobitve:> 01/02/2018
Example of measuring device
Primer merilnega pripomočka
Close the bottle tightly and shake it until the sucrose is completely dissolved.
Plastenko dobro zaprite in jo stresajte, dokler se saharoza popolnoma ne raztopi.
The major contributor to the acaricidal effects is the low pH of the dispersion, as opposed to the volume of dispersion administered.
K akaricidnemu učinku največ prispeva nizka vrednost pH disperzije in ne volumen uporabljene disperzije.
Therefore, if necessary, the dose per seam should be reduced in order not to exceed the maximum total amount administered per colony (calculation: maximum dose per colony/number of occupied seams= x.x ml/seam).
Zato po potrebi zmanjšajte odmerek na posamezen presledek, da ne presežete največje skupne količine na kolonijo (izračun: največji odmerek na kolonijo/število zasedenih presledkov = x,x ml/presledek).
<{MM/YYYY}> <{DD/MM/YYYY}> <{DD month YYYY}>
DATUM REVIZIJE BESEDILA <{MM/LLLL}> <{DD/MM/LLLL}> <{DD. mesec LLLL}>
Other precautions:
Drugi previdnostni ukrepi:
In case the final dispersion had been stored, it should be well shaken before use.
Če ste končno disperzijo imeli shranjeno, jo pred uporabo dobro pretresite.
Do not use this veterinary medicinal product after the expiry date which is stated on the labels and the cardboard box.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini in kartonski škatli.
Repeated treatments are not well tolerated by bees.
Čebele večkratnega zdravljenja ne prenašajo dobro.
In case of eye contact, immediately rinse the eye thoroughly with water (remove contact lenses first).
primeru stika z očmi oko nemudoma in temeljito izperite z vodo (najprej odstranite kontaktne leče).
Personal protective equipment consisting of protective clothing, acid-proof gloves and safety glasses should be worn.
Nosite osebno zaščitno opremo, ki sestoji iz zaščitnih oblačil, rokavic, odpornih proti kislini, in zaščitnih očal.
Do not use during honey flow.
Ne uporabljajte v času čebelje paše.
Dany Bienenwohl GmbH Geyerspergerstr.
Imetnik dovoljenja za promet z zdravilom: Dany Bienenwohl GmbH Geyerspergerstr.
There is evidence that oxalic acid dihydrate dispersion is able to penetrate keratin, as for a short time after application to bees the concentration of oxalic acid dihydrate is slightly increased in all their tissues.
Obstajajo dokazi, da lahko disperzija oksalne kisline dihidrata prodre skozi keratin, saj se za kratek čas po nanosu na čebele koncentracija oksalne kisline dihidrata v vseh njihovih tkivih nekoliko zviša.
If worker bees are treated more than once per generation, it can result in damage to the bees and a reduction in strength of the colony.
Če čebele delavke zdravite več kot enkrat na generacijo, jim lahko škodujete in zmanjšate moč kolonije.
White crystalline powder.
bel kristalni prašek.
No entry Antiinfectious agent
ni smiselno ni vnosa antiinfektiv
Avoid oral exposure, including hand-to-mouth contact.
Izogibajte se peroralni izpostavljenosti, vključno s stikom med roko in usti.
The use of Oxybee with the above dosing scheme only applies to hives with vertical frames that can be accessed from the top, as the treatment of bees in other types of hives has not been investigated.
Uporaba zdravila Oxybee po zgornji shemi odmerjanja velja le za panje s pokončnimi satniki, do katerih lahko dostopate z vrha, saj zdravljenja čebel v drugih vrstah panjev niso proučevali.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 colonies treated displaying adverse reaction(s)) - common (more than 1 but less than 10 colonies in 100 colonies treated) - uncommon (more than 1 but less than 10 colonies in 1,000 colonies treated) - rare (more than 1 but less than 10 colonies in 10,000 colonies treated) - very rare (less than 1 colony in 10,000 colonies treated, including isolated reports.
- zelo pogosti (neželeni učinek(-ki) se pojavi(-jo) pri več kot 1 koloniji od 10 zdravljenih kolonij) - pogosti (pojavijo se pri več kot 1, a manj kot 10 kolonijah od 100 zdravljenih kolonij) - občasni (pojavijo se pri več kot 1, a manj kot 10 kolonijah od 1 000 zdravljenih kolonij) - redki (pojavijo se pri več kot 1, a manj kot 10 kolonijah od 10 000 zdravljenih kolonij) - zelo redki (pojavijo se pri manj kot 1 koloniji od 10 000 zdravljenih kolonij, vključujoč posamezne primere).
The final bee-hive dispersion should be a colourless, clear to slightly turbid dispersion.
Končna disperzija za čebeljo družino mora biti brezbarvna, bistra do rahlo motna disperzija.
The high proportion of sugar in this product increases the viscosity of the dispersion and hence its adhesion to the bees.
Velik delež sladkorja v tem zdravilu poveča viskoznost disperzije, zato se disperzija bolje oprime čebel.
The veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Zdravilo za uporabo v veterinarski medicini ne sme priti v vodotoke, ker je lahko nevarno za ribe in druge vodne organizme.
All colonies in the same apiary should be treated simultaneously to avoid re-infestation.
Vse kolonije v istem čebelnjaku zdravite hkrati, da ne pride do ponovne infestacije.
The veterinary medicinal product should be used as a treatment within an Integrated Varroa Management program with mite drop monitored regularly.
Zdravilo za uporabo v veterinarski medicini je treba uporabljati kot zdravilo v okviru integriranega programa zatiranja varoje z rednim spremljanjem odpada števila pršic.
Oxalic acid is an organic acid used for the treatment of Varroa destructor.
Oksalna kislina je organska kislina, ki se uporablja za zatiranje pršice Varroa destructor.
Oxybee should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Zdravilo Oxybee ne sme priti v vodotoke, ker je lahko nevarno za ribe in druge vodne organizme.
SPECIAL WARNING(S), IF NECESSARY This product has corrosive properties.
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A) To zdravilo ima jedke lastnosti.